Anti-cancer for Acute Respiratory Distress Syndrome

In 2016, a spin out company, Exvastat Ltd was created with intellectual property for the use of an existing anti-cancer drug in the treatment of Acute Respiratory Distress Syndrome, a rare life-threatening condition requiring hospitalisation and intensive care, for this there is no approved therapy.

Exvastat raised venture capital in December 2016 and the first human trials are underway.